Can Investigational Medication Benefit FHP Patients? Request More Information Trial Objective The purpose of this clinical trial is to study the safety and potential benefits of treating fibrotic hypersensitivity pneumonitis (FHP) with an investigational medication. A type of interstitial lung disease (ILD), FHP is scarring of lung tissue from inhaling antigens such as molds, chemicals or dust. This scarring prevents the lungs from moving oxygen from the blood stream to other organs. Currently, more than 1,400 subjects have been treated with this investigational medication in clinical trials. It has been approved by the Food and Drug Administration (FDA) for use in treating idiopathic pulmonary fibrosis, a different type of ILD, but special permission is required to use it to treat FHP. Some study participants will be given the investigational medication and others will receive a placebo. Enrollment This trial is active and currently recruiting. Who Can Participate Adults who have a possible or definite clinical, radiographic or pathologic diagnosis of FHP, according to specific criteria. Participants will be required to have a FVC (forced vital capacity) at or over 40 percent and DLCO (diffusing capacity of the lung for carbon monoxide) at or over 30 percent at screening. Age: 18-80 Gender: Any Gender Estimated Time Commitment 8 visits and 6 phone calls totaling about 12 hours of participation over 13 months Compensation Provided Trial Contact For more information, contact: Kaitlin Fier 303.270.2852 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Genentech, Inc. Principal Investigators Evans Fernández Pérez, MD, MS + × Evans Fernández Pérez, MD, MS Associate Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Request More Information First Name:* Last Name:* Email Address:* Phone:*
Trial Objective The purpose of this clinical trial is to study the safety and potential benefits of treating fibrotic hypersensitivity pneumonitis (FHP) with an investigational medication. A type of interstitial lung disease (ILD), FHP is scarring of lung tissue from inhaling antigens such as molds, chemicals or dust. This scarring prevents the lungs from moving oxygen from the blood stream to other organs. Currently, more than 1,400 subjects have been treated with this investigational medication in clinical trials. It has been approved by the Food and Drug Administration (FDA) for use in treating idiopathic pulmonary fibrosis, a different type of ILD, but special permission is required to use it to treat FHP. Some study participants will be given the investigational medication and others will receive a placebo.